**Table 2. Associations between biomarker trajectories and study endpoints**

| | - 1 SD | Mean | + 1 SD | unadjusted HR | p-value | Adjusted HR* | p-value |
|---|---|---|---|---|---|---|---|
| Myeloperoxidase, ng/ml† | 15.6 | 26.2 | 44.0 | 0.84 (0.61 - 1.26) | 0.32 | 0.84 (0.56 - 1. 37) | 0.44 |
| Galectin 3, ng/ml† | 0.10 | 0.20 | 0.38 | 1.41 (0.77 - 2.42) | 0.27 | 1.56 (0.87 - 2.53) | 0.12 |

*Sensitivity analysis with post 7 days data*

| | - 1 SD | Mean | + 1 SD | unadjusted HR | p-value | Adjusted HR* | p-value |
|---|---|---|---|---|---|---|---|
| Myeloperoxidase, ng/ml‡ | 15.7 | 24.7 | 38.8 | 1.00 (0.62 - 1.69) | 1.00 | 1.18 (0.74 – 1.91) | 0.52 |
| Galectin 3, ng/ml‡ | 0.10 | 0.20 | 0.38 | 1.33 (0.63 - 3.09) | 0.47 | 1.02 (0.48 - 2.15) | 0.95 |

† based on 1478 measurements in 187 patients (median: 8  [IQR: 5-11])

‡ based on 1282 measurements in 174 patients (median: 8  [IQR: 4-10])

*Cox model adjusted for GRACE risk score, mixed model adjusted for GRACE risk score; gender; history of diabetes, coronary artery bypass graft, valvular heart disease, peripheral vessel disease.

HR: hazard ratio; ml: microliter; ng: nanogram; SD: standard deviation